Further data for aflibercept in neovascular age-related macular degeneration

Source: BioSpace
Area: News
BioSpace has reported on the results of an integrated analysis of two Phase III studies (VIEW 1 and VIEW 2) of aflibercept intravitreal injection in the treatment of neovascular age-related macular degeneration (wet AMD).  The 52-week results from the studies have previously been reported; the current data are from a further analysis at 96 weeks. 

Full Story →